HK1211040A1 - New albumin binding compositions, methods and uses - Google Patents
New albumin binding compositions, methods and usesInfo
- Publication number
- HK1211040A1 HK1211040A1 HK15111838.6A HK15111838A HK1211040A1 HK 1211040 A1 HK1211040 A1 HK 1211040A1 HK 15111838 A HK15111838 A HK 15111838A HK 1211040 A1 HK1211040 A1 HK 1211040A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- methods
- albumin binding
- binding compositions
- new albumin
- new
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/61—Growth hormone [GH], i.e. somatotropin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96261807P | 2007-07-31 | 2007-07-31 | |
EP07113533 | 2007-07-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1211040A1 true HK1211040A1 (en) | 2016-05-13 |
Family
ID=40057660
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15111838.6A HK1211040A1 (en) | 2007-07-31 | 2015-12-02 | New albumin binding compositions, methods and uses |
Country Status (11)
Country | Link |
---|---|
US (2) | US8937153B2 (de) |
EP (2) | EP2190863B1 (de) |
JP (1) | JP5718638B2 (de) |
CN (2) | CN104710518A (de) |
AU (1) | AU2008281913B2 (de) |
CA (1) | CA2694139C (de) |
DE (1) | DE08786222T1 (de) |
DK (1) | DK2190863T3 (de) |
ES (1) | ES2346178T3 (de) |
HK (1) | HK1211040A1 (de) |
WO (1) | WO2009016043A2 (de) |
Families Citing this family (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9889197B2 (en) * | 2005-04-15 | 2018-02-13 | Macrogenics, Inc. | Covalently-associated diabody complexes that possess charged coil domains and that are capable of enhanced binding to serum albumin |
CN104710518A (zh) * | 2007-07-31 | 2015-06-17 | 阿菲博迪公司 | 新白蛋白结合组合物、方法及应用 |
ES2548030T3 (es) * | 2009-06-01 | 2015-10-13 | Medimmune, Llc | Moléculas con semividas prolongadas y usos de las mismas |
US9175067B2 (en) * | 2010-03-08 | 2015-11-03 | Ge Healthcare Bio-Sciences Ab | Immunoglobulin G Fc region binding polypeptide |
CN102869676A (zh) * | 2010-04-30 | 2013-01-09 | 株式会社三和化学研究所 | 用于提高生理活性物质等的生物体内稳定性的肽和提高了生物体内稳定性的生理活性物质 |
KR101884654B1 (ko) * | 2010-07-09 | 2018-08-02 | 애피바디 에이비 | 폴리펩타이드 |
EP2621538B1 (de) | 2010-09-28 | 2015-12-16 | Amylin Pharmaceuticals, LLC | Manipulierte polypeptide mit verlängerter wirkungsdauer |
CA3138758A1 (en) | 2010-09-28 | 2012-04-19 | Amylin Pharmaceuticals, Llc | Highly soluble leptins |
CN113278077A (zh) | 2010-11-26 | 2021-08-20 | 分子组合公司 | 设计的与血清白蛋白结合的重复蛋白 |
MX347818B (es) * | 2011-05-21 | 2017-05-15 | Macrogenics Inc | Dominios que enlazan suero desinmunizados y su uso para prolongar la vida media en suero. |
EP2729481B1 (de) * | 2011-07-08 | 2018-10-17 | Amylin Pharmaceuticals, LLC | Manipulierte polypeptide mit verbesserter wirkungsdauer und reduzierter immunogenität |
WO2013009539A1 (en) | 2011-07-08 | 2013-01-17 | Amylin Pharmaceuticals, Inc. | Engineered polypeptides having enhanced duration of action and reduced immunogenicity |
DK2817329T3 (en) | 2012-02-20 | 2019-04-01 | Swedish Orphan Biovitrum Ab Publ | Polypeptides Binding to Human Complement Component C5. |
EP2844269A4 (de) * | 2012-03-28 | 2016-01-06 | Amylin Pharmaceuticals Llc | Transmukosale verabreichung von manipulierten polypeptiden |
JP2020033372A (ja) * | 2012-03-28 | 2020-03-05 | アフィボディ・アーベー | 経口投与 |
WO2013143890A1 (en) | 2012-03-28 | 2013-10-03 | Affibody Ab | Oral administration |
DK2855509T3 (en) | 2012-05-25 | 2018-07-23 | Janssen Biotech Inc | NON-NATURAL CONSENSUS ALBUMIN BINDING DOMAINS |
WO2014048977A1 (en) * | 2012-09-25 | 2014-04-03 | Affibody Ab | Albumin binding polzpeptide |
EP2904013B1 (de) | 2012-10-05 | 2018-11-07 | Affibody AB | Her3-bindende polypeptide |
ES2639099T3 (es) * | 2012-10-25 | 2017-10-25 | Affibody Ab | Polipéptido de unión a albúmina |
JP6396303B2 (ja) * | 2012-10-25 | 2018-09-26 | アフィボディ・アーベー | アルブミン結合を含有するタンパク質の分離方法 |
WO2014076179A1 (en) | 2012-11-14 | 2014-05-22 | Affibody Ab | New polypeptide |
US9255262B2 (en) * | 2013-03-06 | 2016-02-09 | Vision Global Holdings Ltd. | Albumin-binding arginine deminase and the use thereof |
USRE48805E1 (en) | 2013-03-06 | 2021-11-02 | Vision Global Holdings Ltd. | Method for cancer targeting treatment and detection of arginine using albumin-binding arginine deiminase fusion protein |
BR112015021681A2 (pt) | 2013-03-14 | 2017-11-14 | Daiichi Sankyo Co Ltd | proteínas de ligação para pcsk9 |
CA2902789A1 (en) | 2013-03-14 | 2014-09-18 | The Governing Council Of The University Of Toronto | Scaffolded peptidic libraries and methods of making and screening the same |
CN105209482B (zh) | 2013-03-15 | 2022-04-29 | 阿菲博迪公司 | 新的多肽 |
BR112015026122A8 (pt) | 2013-04-18 | 2020-01-21 | Armo Biosciences Inc | agente de polietileno glicol-il-10 (peg-il-10), seu uso, composição farmacêutica, contentor estéril e kit |
WO2014204816A2 (en) | 2013-06-17 | 2014-12-24 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
LT3039033T (lt) | 2013-08-28 | 2019-10-25 | Affibody Ab | Surišantys polipeptidai, turintys mutuotą karkasą |
CA2926976C (en) | 2013-08-28 | 2023-11-28 | Swedish Orphan Biovitrum Ab (Publ) | Stable polypeptides binding to human complement c5 |
CN105658232A (zh) | 2013-08-30 | 2016-06-08 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素-10治疗疾病和病症的方法 |
US11413332B2 (en) | 2013-11-11 | 2022-08-16 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
US10167322B2 (en) | 2013-12-20 | 2019-01-01 | Affibody Ab | Engineered albumin binding polypeptide |
US10293043B2 (en) | 2014-06-02 | 2019-05-21 | Armo Biosciences, Inc. | Methods of lowering serum cholesterol |
MD20170020A2 (ro) | 2014-07-30 | 2017-07-31 | Ngm Biopharmaceuticals, Inc. | Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice |
JP6940405B2 (ja) | 2014-09-17 | 2021-09-29 | アフィボディ アクティエボラーグ | 新規ポリペプチド |
US10350270B2 (en) | 2014-10-14 | 2019-07-16 | Armo Biosciences, Inc. | Interleukin-15 compositions and uses thereof |
US10143726B2 (en) | 2014-10-22 | 2018-12-04 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
SG11201702580PA (en) | 2014-10-31 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Compositions and methods of use for treating metabolic disorders |
PL3245224T3 (pl) | 2015-01-12 | 2021-01-25 | Affibody Ab | Polipeptydy wiążące il-17a |
US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
EP3291828A4 (de) * | 2015-05-06 | 2018-10-03 | Alborz Mahdavi | Glucoseempfindliche insuline |
WO2016191587A1 (en) | 2015-05-28 | 2016-12-01 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
US11458205B2 (en) | 2015-08-04 | 2022-10-04 | Duke University | Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same |
WO2017035232A1 (en) | 2015-08-25 | 2017-03-02 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
US11752213B2 (en) | 2015-12-21 | 2023-09-12 | Duke University | Surfaces having reduced non-specific binding and antigenicity |
CN107022031A (zh) * | 2016-01-29 | 2017-08-08 | 中国人民解放军军事医学科学院微生物流行病研究所 | 融合蛋白HSA1-Vβ1及其应用 |
WO2017210476A1 (en) | 2016-06-01 | 2017-12-07 | Duke University | Nonfouling biosensors |
JP2020500150A (ja) | 2016-09-23 | 2020-01-09 | デューク ユニバーシティ | 下限臨界溶液温度挙動を有する非反復かつ非構造的ポリペプチド |
CN107952080A (zh) * | 2016-10-14 | 2018-04-24 | 中国科学院过程工程研究所 | 一种肿瘤靶向多肽-药物偶联衍生物、其制备方法及应用 |
US11648200B2 (en) | 2017-01-12 | 2023-05-16 | Duke University | Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly |
US11554097B2 (en) | 2017-05-15 | 2023-01-17 | Duke University | Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents |
US11680083B2 (en) | 2017-06-30 | 2023-06-20 | Duke University | Order and disorder as a design principle for stimuli-responsive biopolymer networks |
EP3665202A1 (de) | 2017-08-09 | 2020-06-17 | Massachusetts Institute Of Technology | Albumin-bindende peptidkonjugate und verfahren dafür |
WO2019071150A1 (en) * | 2017-10-06 | 2019-04-11 | University Of Utah Research Foundation | FUSION PROTEIN FOR TARGETED THERAPY OF AUTOIMMUNE DISEASE |
US20200239575A1 (en) * | 2017-10-06 | 2020-07-30 | University Of Utah Research Foundation | A fusion protein for targeted therapy of autoimmune disease |
EP3765496A1 (de) | 2018-03-13 | 2021-01-20 | Affibody AB | Polypeptide auf der basis eines neuen gerüsts |
EP3788343B1 (de) | 2018-04-30 | 2024-03-27 | Duke University | Auf stimuli reagierende plattform zur abgabe von auf peg-like-polymer basierendem arzneimittel |
EP3829622A4 (de) | 2018-08-02 | 2022-05-11 | Duke University | Doppel-agonisten-fusionsproteine |
US20210316007A1 (en) * | 2018-09-07 | 2021-10-14 | Duke University | Nanoparticulate drug delivery systems |
US11512314B2 (en) | 2019-07-12 | 2022-11-29 | Duke University | Amphiphilic polynucleotides |
WO2021043757A1 (en) | 2019-09-02 | 2021-03-11 | Biotest Ag | Factor viii protein with increased half-life |
EP3785726A1 (de) | 2019-09-02 | 2021-03-03 | Biotest AG | Faktor-viii-protein mit erhöhter halbwertszeit |
WO2021089695A1 (en) | 2019-11-05 | 2021-05-14 | Affibody Ab | Polypeptides |
WO2021165226A1 (en) | 2020-02-17 | 2021-08-26 | Biotest Ag | Subcutaneous administration of factor viii |
EP3878515A1 (de) * | 2020-03-09 | 2021-09-15 | Hober Biotech AB | Her2 zielender therapeutischer wirkstoff |
WO2022098743A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, imaging, and therapeutic methods targeting folate receptor 1 (folr1) |
WO2022098745A1 (en) | 2020-11-03 | 2022-05-12 | Indi Molecular, Inc. | Compositions, delivery systems, and methods useful in tumor therapy |
CA3200702A1 (en) | 2020-12-21 | 2022-06-30 | Affibody Ab | New polypeptide |
JP2024506070A (ja) | 2021-02-15 | 2024-02-08 | アフィボディ アクティエボラーグ | 新規her2結合ポリペプチド |
WO2023152144A1 (en) | 2022-02-08 | 2023-08-17 | Affibody Ab | Protein z variants binding thymic stromal lymphopoietin and their medical use |
KR20250005573A (ko) | 2022-05-18 | 2025-01-09 | 프로토머 테크놀로지스 인크. | 방향족 붕소-함유 화합물 및 관련 인슐린 유사체 |
CN119677787A (zh) | 2022-08-10 | 2025-03-21 | 兴和株式会社 | 亲和体微胞药物复合体 |
US20240368250A1 (en) | 2023-02-17 | 2024-11-07 | Ablynx N.V. | Polypeptides binding to the neonatal fc receptor |
WO2024227930A1 (en) | 2023-05-04 | 2024-11-07 | Affibody Ab | New polypeptide |
CN118666961B (zh) * | 2024-08-23 | 2024-11-26 | 通化安睿特生物制药股份有限公司 | 人白蛋白特异结合多肽及其应用 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE509359C2 (sv) | 1989-08-01 | 1999-01-18 | Cemu Bioteknik Ab | Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel |
FR2718452B1 (fr) * | 1994-04-06 | 1996-06-28 | Pf Medicament | Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation. |
FR2726471B1 (fr) * | 1994-11-07 | 1997-01-31 | Pf Medicament | Procede pour ameliorer l'immunogenicite d'un compose immunogene ou d'un haptene et application a la preparation de vaccins |
DE19742706B4 (de) * | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
GB9823071D0 (en) * | 1998-10-21 | 1998-12-16 | Affibody Technology Ab | A method |
GB9911287D0 (en) * | 1999-05-14 | 1999-07-14 | Affibody Technology Sweden Ab | Self-assembling protein structures |
US20040001827A1 (en) | 2002-06-28 | 2004-01-01 | Dennis Mark S. | Serum albumin binding peptides for tumor targeting |
EP2180054A1 (de) | 1999-12-24 | 2010-04-28 | Genentech, Inc. | Verfahren und Zusammenstellungen zur Verlängerung der Entsorgungshalbzeiten von bioaktiven Verbindungen |
CN1169827C (zh) | 2001-08-07 | 2004-10-06 | 沈阳三生制药股份有限公司 | 一种增强多肽在体内稳定性药物的生产方法及其应用 |
CA2464690A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of apolipoprotein d |
WO2003029462A1 (en) * | 2001-09-27 | 2003-04-10 | Pieris Proteolab Ag | Muteins of human neutrophil gelatinase-associated lipocalin and related proteins |
SE0400274D0 (sv) * | 2004-02-09 | 2004-02-09 | Affibody Ab | New polypeptide |
US8642743B2 (en) | 2004-04-06 | 2014-02-04 | Affibody Ab | Method for reducing the immune response to a biologically active protein |
EP1814988A2 (de) * | 2004-11-26 | 2007-08-08 | Pieris AG | Verbingung mit affinität für das zytotoxische t-lymphozyte-assoziierte antigen (ctla-4) |
CN104710518A (zh) * | 2007-07-31 | 2015-06-17 | 阿菲博迪公司 | 新白蛋白结合组合物、方法及应用 |
US10208128B2 (en) * | 2009-11-04 | 2019-02-19 | Affibody Ab | HER3 binding polypeptides |
-
2008
- 2008-07-17 CN CN201510071238.8A patent/CN104710518A/zh active Pending
- 2008-07-17 AU AU2008281913A patent/AU2008281913B2/en active Active
- 2008-07-17 JP JP2010518606A patent/JP5718638B2/ja active Active
- 2008-07-17 WO PCT/EP2008/059389 patent/WO2009016043A2/en active Application Filing
- 2008-07-17 CN CN200880101168.4A patent/CN101765608B/zh active Active
- 2008-07-17 EP EP08786222.3A patent/EP2190863B1/de active Active
- 2008-07-17 DK DK08786222.3T patent/DK2190863T3/da active
- 2008-07-17 DE DE08786222T patent/DE08786222T1/de active Pending
- 2008-07-17 EP EP12176805.5A patent/EP2546261A3/de not_active Withdrawn
- 2008-07-17 ES ES08786222.3T patent/ES2346178T3/es active Active
- 2008-07-17 CA CA2694139A patent/CA2694139C/en active Active
- 2008-07-17 US US12/452,731 patent/US8937153B2/en active Active
-
2014
- 2014-11-24 US US14/551,931 patent/US10118949B2/en active Active
-
2015
- 2015-12-02 HK HK15111838.6A patent/HK1211040A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
ES2346178T3 (es) | 2015-11-02 |
CN101765608A (zh) | 2010-06-30 |
US20100273979A1 (en) | 2010-10-28 |
US8937153B2 (en) | 2015-01-20 |
AU2008281913A1 (en) | 2009-02-05 |
DK2190863T3 (en) | 2015-11-30 |
CA2694139A1 (en) | 2009-02-05 |
US10118949B2 (en) | 2018-11-06 |
EP2546261A3 (de) | 2013-08-14 |
US20150158916A1 (en) | 2015-06-11 |
EP2190863B1 (de) | 2015-09-02 |
CA2694139C (en) | 2018-06-05 |
JP5718638B2 (ja) | 2015-05-13 |
JP2010534486A (ja) | 2010-11-11 |
AU2008281913B2 (en) | 2013-11-07 |
WO2009016043A3 (en) | 2009-06-04 |
ES2346178T1 (es) | 2010-10-13 |
CN101765608B (zh) | 2015-03-11 |
EP2190863A2 (de) | 2010-06-02 |
WO2009016043A2 (en) | 2009-02-05 |
CN104710518A (zh) | 2015-06-17 |
EP2546261A2 (de) | 2013-01-16 |
DE08786222T1 (de) | 2010-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211040A1 (en) | New albumin binding compositions, methods and uses | |
HRP20181353T1 (hr) | Tuberkulozni protein rv2386c, njegovi pripravci i upotreba | |
IL211284A0 (en) | Antibodies binding ccr2, compositions comprising the same and uses thereof | |
IL230759A0 (en) | Converted acyl anilide, the pharmaceutical composition containing it and its uses | |
GB0601143D0 (en) | Uses, methods and compositions | |
EP2069401A4 (de) | Multispezifische epitop-bindende proteine und ihre verwendung | |
IL226339B (en) | Aptamers that bind to 5c, preparations containing them and their uses | |
ZA201001300B (en) | Antigen-asjuvant compositions and methods | |
EP2076604A4 (de) | Glp-2-mimetikörper, polypeptide, zusammensetzungen, verfahren und verwendungen | |
ZA201005278B (en) | Folates, compositions and uses thereof | |
GB0706077D0 (en) | Methods, Compositions and uses thereof | |
IL205966A0 (en) | Oligomer-tricyclic conjugates, compositions comprising the same and uses thereof | |
GB0721291D0 (en) | Methods and compositions | |
EP2214690A4 (de) | Den melanocortinrezeptor bindende mimetikörper, zusammensetzungen, verfahren und verwendungen | |
IL202996A0 (en) | Anti-mcp-1 antibodies, compositions, methods and uses | |
GB0719526D0 (en) | Compositions and methods | |
GB0819432D0 (en) | Compound, composition and use | |
GB2453860B (en) | Ionizing-radiation-responsive compositions,methods and systems | |
HK1154245A1 (en) | Phenanthrenone compounds, compositions and methods | |
ZA201006443B (en) | Novel immunoregularory peptides,compositions and uses thereof | |
EP2186647A4 (de) | Bügel und aktenordner damit | |
GB0612917D0 (en) | Metallic compositions,preparations and uses | |
EP2186646A4 (de) | Bügel und aktenordner damit | |
GB0616621D0 (en) | Mite composition, composition use and methods | |
GB0720489D0 (en) | Novel mixtures, compositions and ususe |